MedTrace Logo

Predictive Model for the Occurrence of Cerebral Vasospasm Complicating Subarachnoid Haemorrhage by Combined Analysis of the Kinetics of a Panel of Biomarkers.

NCT06303349 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2025-08-06

No results posted yet for this study

Summary

The objective is to create a dynamic clinical prediction model that includes routinely measured care and biological biomarkers to predict cerebral vasospasm within 14 days of bleeding in patients treated in the neurosurgical intensive care unit for subarachnoid hemorrhage.

Patients admitted to intensive care will be followed for up to 14 days (D14 time horizon of interest), or until discharge from intensive care if earlier.

Blood samples will be taken from D1 to D10 to isolate the blood biomarkers of interest for each patient.

The measurement of biomarkers and cerebral vasospasm will be blinded to each other.

Conditions

  • Cerebral Vasospasm

Interventions

OTHER

Samples collection

from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected. 1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it.

Sponsors & Collaborators

  • University of Bordeaux

    collaborator OTHER

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Grégoire CANE, Dr · University Hospital, Bordeaux

  • Hugues De COURSON, Dr · University Hospital, Bordeaux

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-07
Primary Completion
2025-05-16
Completion
2025-05-16

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06303349 on ClinicalTrials.gov